We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impaired hepatic Gd-EOB-DTPA enhancement after radioembolisation of liver malignancies.
- Authors
Powerski, Maciej Janusz; Scheurig‐Münkler, Christian; Hamm, Bernd; Gebauer, Bernhard
- Abstract
Introduction To evaluate the uptake of the liver-specific magnetic resonance imaging ( MRI) contrast agent gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid ( Gd-EOB-DTPA) by functional liver parenchyma after radioembolisation ( RE) of hepatic malignancies. Methods Uptake of Gd-EOB-DTPA prior to RE versus 60+/−24d and 126+/−32d after RE was compared in a group of 33 patients with primary or secondary hepatic malignancies. In patients who underwent single-lobe treatment, left and right lobes were compared 59+/−24 days after RE. Gd-EOB-DTPA uptake was determined as follows: ratio of mean signal intensity in liver parenchyma to muscle in Gd-EOB-DTPA-enhanced T1-weighted MRI was subtracted from ratio of mean intensity in liver parenchyma to muscle in unenhanced T1-weighted MRI. Results Gd-EOB-DTPA uptake in liver parenchyma was 0.845+/−0.29 before RE, 0.615+/−0.38 ( P = 0.0022) at day 60+/−24, and 0.739+/−0.30 at day 126+/−32 after RE. In cases of single-lobe treatment, Gd-EOB-DTPA uptake was 0.581+/−0.256 for treated and 0.828+/−0.32 ( P = 0.0164) for untreated hepatic lobes. Conclusions Uptake of Gd-EOB-DTPA by liver parenchyma is impaired after RE, indicating dysfunction of the local hepatic system. These findings suggest that Gd-EOB-DTPA-enhanced MRI has the potential to be used for monitoring liver damage after RE.
- Subjects
LIVER tumors; MAGNETIC resonance imaging; RADIOEMBOLIZATION; THERAPEUTIC embolization; CANCER treatment; GADOLINIUM compounds; RADIOISOTOPE brachytherapy
- Publication
Journal of Medical Imaging & Radiation Oncology, 2014, Vol 58, Issue 4, p472
- ISSN
1754-9477
- Publication type
Article
- DOI
10.1111/1754-9485.12187